116296-31-2 Usage
Biological Activity
3-thiatetradecanoic acid is an activator of ppar.the peroxisome proliferator-activated receptors (ppars) are transcription factors involved in fatty acid metabolism and energy homeostasis. the ppars also play crucial roles in the control of cellular growth and differentiation.
in vitro
in bt4cn cells, 3-thiatetradecanoic acid could activate all ppar subtypes dose-dependently. in cell culture experiments, the pparγ-selective ligand brl49653 moderately inhibited growth of bt4cn cells, while administration of 3-thiatetradecanoic acid led to a marked growth inhibition. moreover, the administration of the pparγ-selective antagonist gw9662 abolished brl49653-induced growth inhibition, but only marginally reduced the effect of 3-thiatetradecanoic acid [1].
in vivo
administration of 3-thiatetradecanoic acid increased mitochondrial and peroxisomal beta-oxidative capacity and carnitine palmitoyltransferase activity, but reduced free fatty acid and triacylglycerol levels in plasma compared to palmitic acid-treated rats and controls. 3-thiatetradecanoic acid administration was able to affect the fatty acid composition in plasma and liver by increasing the amount of monoenes [2].
references
1. berge k, tronstad kj, flindt en, rasmussen th, madsen l, kristiansen k, berge rk. tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via ppar-dependent and ppar-independent pathways. carcinogenesis. 2001 nov;22(11):1747-55.2. asiedu, d.k.,froyland, l.,vaagenes, h., et al. long-term effect of tetradecylthioacetic acid: a study on plasma lipid profile and fatty acid composition and oxidation in different rat organs. biochimica et biophysica acta 1300, 86-96 (1996).3. pettersen rj, salem m, skorve j, ulvik rj, berge rk, nordrehaug je. pharmacology and safety of tetradecylthioacetic acid (tta): phase-1 study. j cardiovasc pharmacol. 2008 apr;51(4):410-7.
Check Digit Verification of cas no
The CAS Registry Mumber 116296-31-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,2,9 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 116296-31:
(8*1)+(7*1)+(6*6)+(5*2)+(4*9)+(3*6)+(2*3)+(1*1)=122
122 % 10 = 2
So 116296-31-2 is a valid CAS Registry Number.
116296-31-2Relevant articles and documents
Structure-activity relationship studies of (E)-3,4-dihydroxystyryl alkyl sulfones as novel neuroprotective agents based on improved antioxidant, anti-inflammatory activities and BBB permeability
Chen, Ying,Wu, Bolin,Hao, Yameng,Liu, Yunqi,Zhang, Zhili,Tian, Chao,Ning, Xianling,Guo, Ying,Liu, Junyi,Wang, Xiaowei
supporting information, p. 420 - 433 (2019/03/29)
(E)-3,4-dihydroxystyryl alkyl sulfones, as new analogues of neurodegenerative agents, were designed and synthesized. The biological results demonstrated that most of the target compounds preserved antioxidant and anti-inflammatory potency in scavenging reactive free radicals, protecting neuronal cells against neurotoxins such as H2O2, 6-hydroxydopamine and inhibiting lipopolysaccharide (LPS)-induced over-production of NO. Among these compounds, 6.22 with cyclopentyl propyl exhibited prominent antioxidant activity at low concentration (2.5 μM) in H2O2 model (cell viability = 94.5%). In addition, 6.22 (IC50 = 1.6 μM) displayed better anti-inflammatory activity than that of lead compound 1 (IC50 = 13.4 μM). In view of the outstanding performance of 6.22, the apoptotic rates of H2O2-damaged PC12 cells were detected by Annexin V-FITC/PI assay. 6.22 showed higher potency in inhibition of apoptosis than 1 at low concentration (2.5 μM), consisting with the antioxidant and anti-inflammatory models. Furthermore, with the predicted CNS (+) blood-brain barrier (BBB) permeability (Pe = 6.84 × 10?6 cm s?1), low cytotoxicity and favorable physiochemical properties based on calculation, compound 6.22 can be further developed as a potential multifunctional neuroprotective agent.
